Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT)

Clin Lymphoma Myeloma. 2006 Mar;6(5):423-6. doi: 10.3816/CLM.2006.n.024.

Author

Affiliation

¹ Hematology Section, Department of Medicine/University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792, USA. bsk@medicine.wisc.edu

PMID: 16640824
DOI: 10.3816/CLM.2006.n.024

No abstract available

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Murine-Derived
Biopsy, Needle
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Immunohistochemistry
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / mortality
Lymphoma, Non-Hodgkin / pathology*
Male
Maximum Tolerated Dose
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / mortality
Neoplasm Recurrence, Local / pathology
Neoplasm Staging
Randomized Controlled Trials as Topic*
Research Design
Risk Assessment
Rituximab
Survival Rate
Treatment Outcome
United States

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Rituximab